SynAct Pharma AB's total assets for Q4 2024 were kr270.52M, an increase of 24.59% from the previous quarter. DE:8F8 total liabilities were kr56.35M for the fiscal quarter, a 17.48% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.